MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy, the first ...

The treatment is indicated for patients with locally advanced biliary tract cancer which cannot be surgically resected or has metastasised. Durvalumab is the first immunotherapy to be offered as ...

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

Several of these same peptides could also distinguish BTC from benign cases of biliary disease albeit with lower accuracy, though none were discriminatory when using a smaller subset of 10 samples ...

Three of the total 103 research projects on the list involve researchers at KI: AI for early detection and prognosis of ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Read more about A study looking at AZD8205 for cancer that has spread or come back after treatment (Sub-study 1) This trial was done to find out if oxaliplatin and 5FU is useful for people with ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...

PDUFA date for potential approval of Zanidatamab is set for Nov 29, developed in collaboration with Jazz Pharmaceuticals and BeiGene. Find out why ZYME stock is a Buy.

Read more about A trial looking at having a stent with or without photodynamic therapy for symptoms of advanced biliary tract cancer (PHOTOSTENT - 02) This study is looking at the side effects of ...